Six years af­ter a spec­tac­u­lar de­but, Warp Dri­ve Bio is pow­er­ing down and hand­ing its 'un­drug­gable' am­bi­tions over to Rev­o­lu­tion

Close to six years af­ter Third Rock launched Warp Dri­ve Bio with a big-mon­ey col­lab­o­ra­tion from Sanofi and am­bi­tious plans to drug the un­drug­gable with new tech out of Har­vard, the biotech has reached the end of the line as an in­de­pen­dent op­er­a­tion. 

To­day Warp Dri­ve is dis­patch­ing its pipeline to an­oth­er Third Rock start­up com­pa­ny, Rev­o­lu­tion Med­i­cines, with the CEOs of both com­pa­nies in­sist­ing that this is a win-win for all in­volved, though Warp Dri­ve nev­er ac­tu­al­ly made the leap in­to the clin­ic.

Endpoints News

Unlock this article instantly by becoming a free subscriber.

You’ll get access to free articles each month, plus you can customize what newsletters get delivered to your inbox each week, including breaking news.